Sihuan Pharmaceutical Holdings Group Ltd.
SHPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 1.01 | 0.01 | -1.30 |
| FCF Yield | 1.73% | -1.82% | -5.53% | 0.67% |
| EV / EBITDA | 6.47 | 7.91 | -2.53 | 5.35 |
| Quality | ||||
| ROIC | -1.86% | 2.09% | -20.61% | 3.45% |
| Gross Margin | 65.32% | 69.64% | 68.20% | 79.99% |
| Cash Conversion Ratio | -0.57 | -1.24 | -0.02 | 1.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.48% | -15.08% | -3.99% | 1.82% |
| Free Cash Flow Growth | 159.95% | 73.05% | -653.81% | 123.00% |
| Safety | ||||
| Net Debt / EBITDA | -25.20 | -7.88 | 1.65 | -4.94 |
| Interest Coverage | -0.50 | 0.60 | -8.67 | 6.58 |
| Efficiency | ||||
| Inventory Turnover | 1.58 | 1.01 | 1.14 | 0.85 |
| Cash Conversion Cycle | 347.51 | 295.61 | 298.37 | 451.68 |